Browse > Article
http://dx.doi.org/10.7314/APJCP.2012.13.6.2791

DNA Repair Gene ERCC1 and XPD Polymorphisms Predict Glioma Susceptibility and Prognosis  

Chen, Da-Qing (The Affiliated Union Hospital, Tongji Medical College, Huazhong University of Science and Technology)
Yao, Dong-Xiao (The Affiliated Union Hospital, Tongji Medical College, Huazhong University of Science and Technology)
Zhao, Hong-Yang (The Affiliated Union Hospital, Tongji Medical College, Huazhong University of Science and Technology)
Yang, Shu-Juan (West China School of Public Health, Sichuan University)
Publication Information
Asian Pacific Journal of Cancer Prevention / v.13, no.6, 2012 , pp. 2791-2794 More about this Journal
Abstract
Aims: We conducted a case-control study in a Chinese population to clarify the association between polymorphisms in ERCC1 and XPD and susceptibility and survival of glioma. Methods: A total of 393 cases and 410 controls were selected from March 2007 to December 2011. Genotyping of ERCC1 and XPD was conducted by TaqMan assays using the ABI Prism 7911HT Sequence Detection System. All analyses were performed using the STATA statistical package. Results: Polymorphisms in ERCC1 118C/T, ERCC1 8092C/A and XPD Asp312Asn showed no statistically significant difference between glioma cases and controls. However, individuals with the XPD 751Gln/Gln genotype had an increased risk of developing glioma compared with those with the Lys/Lys genotype (adjusted OR=1.64, 95% CI: 1.06-2.89). The ERCC1 118T/T genotype was associated with significantly higher median survival than the ERCC1 C/C genotype (HR=0.67, 95%CI=0.35-0.96). In addition, individuals with XPD 751Gln/Gln had a lower median survival time than XPD Lys/Lys carriers (HR=0.54, 95%CI=0.37-0.93). Conclusion: In conclusion, we observed that the XPD 751Gln/Gln genotype is associated with glioma susceptibility, and ERCC1 118 T/T and XPD 751Gln/Gln genotypes confer a significantly better prognosis.
Keywords
ERCC1; XPD; polymorphisms; glioma; susceptibility; prognosis;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Altaha R, Liang X, Yu JJ, et al (2004). Excision repair cross complementing-group 1: gene expression and platinum resistance. Int J Mol Med, 14, 959-70.
2 Batchelor TT, Betensky RA, Esposito JM, et al (2004). Agedependent prognostic effects of genetic alterations in glioblastoma. Clin Cancer Res, 10, 228-33.   DOI
3 Benhamou S, Sarasin A (2002). ERCC2/XPD gene polymorphisms and cancer risk. Mutagenesis, 17, 463-9.   DOI   ScienceOn
4 Benhamou S, Sarasin A (2005). ERCC2 /XPD gene polymorphisms and lung cancer: a Huge review. Am J Epidemiol, 161, 1-14.   DOI
5 Braithwaite E, Wu X, Wang Z (1999). Repair of DNA lesions: mechanisms and relative repair efficiencies. Mutat Res, 424, 207-19.   DOI
6 Chen HY, Shao CJ, Shi HL, et al (2007). Single nucleotide polymorphisms and expression of ERCC1 and ERCC2 visa- vis chemotherapy drug cytotoxicity in human glioma. J Neurooncol, 82, 257-62.   DOI
7 Coin F, Bergmann E, Tremeau-Bravard A, et al (1999). Mutations in XPB and XPD helicases found in xeroderma pigmentosum patients impair the transcription function of TFIIH. Embo J, 18, 1357-66.   DOI
8 de Laat WL, Jaspers NG, Hoeijmakers JH(1999). Molecular mechanism of nucleotide excision repair. Genes Dev, 13, 768-85.   DOI
9 Flejter WL, McDaniel LD, Johns D, et al (1992). Correction of xeroderma pigmentosum complementation group D mutant cell phenotypes by chromosome and gene transfer: involvement of the human ERCC2 DNA repair gene. Proc Natl Acad Sci USA, 89, 261-5.   DOI
10 Goyal S, Parikh RR, Green C, et al (2010). Clinicopathologic significance of excision repair cross-complementation 1 expression in patients treated with breast-conserving surgery and radiation therapy. Int J Radiat Oncol Biol Phys, 76, 679-84.   DOI
11 Hayes M, Lan C, Yan J, et al (2011). ERCC1 expression and outcomes in head and neck cancer treated with concurrent cisplatin and radiation. Anticancer Res, 31, 4135-9.
12 Houillier C, Lejeune J, Benouaich-Amiel A, et al(2006). Prognostic impact of molecular markers in a series of 220 primary glioblastomas. Cancer, 106, 2218-23.   DOI
13 Hu XB, Feng Z, Fan YC, et al (2011). Polymorphisms in DNA repair gene XRCC1 and increased genetic susceptibility to glioma. Asian Pac J Cancer Prev, 12, 2981-4.
14 Jensen NF, Smith DH, Nygard SB, et al (2012). Predictive biomarkers with potential of converting conventional chemotherapy to targeted therapy in patients with metastatic colorectal cancer. Scand J Gastroenterol, 47, 340-55.   DOI
15 Kiuru A, LindholmC, Heinavaara S, et al (2008). XRCC1 and XRCC3 variants and risk of glioma and meningioma. J Neurooncol, 88, 135-142.   DOI
16 Liao WY, Shih JY, Chang GC, et al (2012). Genetic polymorphism of XRCC1 Arg399Gln is associated with survival in nonsmall- cell lung cancer patients treated with gemcitabine/ platinum. J Thorac Oncol, 7, 973-81.   DOI
17 Kuwabara K, Kumamoto K, Ishibashi K, et al (2011). The Relationship between the efficacy of mFOLFOX6 treatment and the expression of TS, DPD, TP, and ERCC-1 in unresectable colorectal cancer. Gan To Kagaku Ryoho, 38, 2224-7.
18 Leichman L, Lawrence D, Leichman CG, et al (2006). Expression of genes related to activity of oxaliplatin and 5-fluorouracil in endoscopic biopsies of primary esophageal cancer in patients receiving oxaliplatin, 5-flourouracil and radiation: characterization and exploratory analysis with survival. J Chemother, 18, 514-24.   DOI
19 Leng XF, Chen MW, Xian L, et al (2012). Combined analysis of mRNA expression of ERCC1, BAG-1, BRCA1, RRM1 and TUBB3 to predict prognosis in patients with non-small cell lung cancer who received adjuvant chemotherapy. J Exp Clin Cancer Res, 31, 25.   DOI   ScienceOn
20 Lindahl T, Karran P, Wood RD (1997). DNA excision repair pathways. Curr Opin Genet Dev, 7, 158-69.   DOI   ScienceOn
21 Liu Y, Scheurer ME, El-Zein R, et al (2009). Association and interactions between DNA repair gene polymorphisms and adult glioma. Cancer Epidemiol Biomarkers Prev, 18, 204-14.   DOI
22 Milovic-Kovacevic M, Srdic-Rajic T, Radulovic S, et al(2011). Expression of ERCC1 protein in biopsy specimen predicts survival in advanced ovarian cancer patients treated with platinum-based chemotherapy. J BUON, 16, 708-14.
23 Ohgaki H, Dessen P, Jourde B, et al(2004). Genetic pathways to glioblastoma: A population-based study. Cancer Res, 64, 6892-9.   DOI   ScienceOn
24 Wang LE, Bondy ML, Shen H, et al (2004). Polymorphisms of DNA repair genes and risk of glioma. Cancer Res, 64, 5560-3.   DOI
25 Rajaraman P, Hutchinson A, Wichner S, et al (2010). DNA repair gene polymorphisms and risk of adult meningioma, glioma, and acoustic neuroma. Neuro Oncol, 12, 37-48.   DOI
26 Rich JN, Hans C, Jones B, et al (2005). Gene expression profiling and genetic markers in glioblastoma survival. Cancer Res, 65, 4051-508.   DOI
27 Sung P, Bailly V, Weber C, et al (1993). Human xeroderma pigmentosum group D gene encodes a DNA helicase. Nature, 365, 852-5.   DOI
28 Weeda G, Hoeijmakers JH(1993). Genetic analysis of nucleotide excision repair in mammalian cells. Semin Cancer Biol, 4, 105-17.
29 Wrensch M, Kelsey KT, Liu M, et al (2005). ERCC1 and ERCC2 polymorphisms and adult glioma. Neuro Oncol, 7, 495-507.   DOI
30 Yan L, Shu-Ying Y, Shan K, et al (2012). Association between polymorphisms of ERCC1 and survival in epithelial ovarian cancer patients with chemotherapy. Pharmacogenomics, 13, 419-27.   DOI
31 Yosunkaya E, Kucukyuruk B, Onaran I, et al (2010). Glioma risk associateswith polymorphisms of DNA repair genes, XRCC1 and PARP1. Br J Neurosurg, 24, 561-5.   DOI
32 Zhang N, Lin LY, Zhu LL, et al (2012). ERCC1 polymorphisms and risk of adult glioma in a Chinese population: a hospitalbased case-control study. Cancer Invest, 30, 199-202.   DOI
33 Zhou K, Liu Y, Zhang H, et al (2009). XRCC3 haplotypes and risk of gliomas in a Chinese population: a hospital-based case-control study. Int J Cancer, 124, 2948-53.   DOI
34 Zhou LQ, Ma Z, Shi XF, et al (2011). Polymorphisms of DNA repair gene XRCC1 and risk of glioma: a case-control study in Southern China. Asian Pac J Cancer Prev, 12, 2547-50.